For example, in the case of breast cancer subtypes that overexpress epidermal growth factor receptor 2 (EGFR2/HER2/Neu; generally called HER2+), the introduction of the humanized monoclonal antibody trastuzumab (Herceptin®) and other HER2-targeted agents resulted in significantly improved treatment outcomes for the peripheral disease. Here, ERBB2 is linked to breast cancer.